Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$27.54 USD
-0.45 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $27.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Cash flow Statements
Fiscal Year End for Royalty Pharma PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 1,700.09 | 230.06 | 1,241.20 | 1,701.95 | 2,461.42 |
Depreciation/Amortization & Depletion | 20.50 | 27.03 | 43.16 | 34.77 | 36.71 |
Net Change from Assets/Liabilities | 1,009.04 | 414.80 | 218.36 | 202.96 | 260.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 258.18 | 1,472.09 | 514.82 | 94.94 | -1,091.48 |
Net Cash From Operating Activities | 2,987.80 | 2,143.98 | 2,017.54 | 2,034.63 | 1,667.24 |
Property & Equipment | 0.00 | -1,741.64 | -2,191.50 | -2,182.25 | -1,721.29 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -21.22 | 0.00 | 0.00 | 0.00 |
Investments | -2,070.75 | 712.22 | 320.70 | -592.16 | -432.33 |
Other Investing Activities | -2.04 | 0.00 | 0.52 | 15.08 | 0.00 |
Net Cash from Investing Activities | -2,072.79 | -1,029.42 | -1,870.28 | -2,759.32 | -2,153.63 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -297.28 | 7.19 | 44.21 | 1,976.18 | -4.27 |
Issuance (Repayment) of Debt | -1,000.00 | 0.00 | 1,272.53 | 680.63 | -294.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -854.85 | -950.70 | -918.59 | -1,122.93 | -893.36 |
Other Financing Activities | 3.38 | -1.35 | -13.05 | -46.72 | 0.00 |
Net Cash from Financing Activities | -2,148.75 | -944.86 | 385.11 | 1,487.17 | -1,191.63 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1,233.74 | 169.70 | 532.37 | 762.48 | -1,678.01 |
Cash at Beginning of Period | 1,710.75 | 1,541.05 | 1,008.68 | 246.20 | 1,924.21 |
Cash at End of Period | 477.01 | 1,710.75 | 1,541.05 | 1,008.68 | 246.20 |
Diluted Net EPS | 2.53 | 0.10 | 1.49 | 1.32 | NA |
Fiscal Year End for Royalty Pharma PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 190.10 | -4.27 | 1,700.09 | 982.50 | 860.43 |
Depreciation/Amortization & Depletion | 8.91 | 4.35 | 20.50 | 15.66 | 10.65 |
Net Change from Assets/Liabilities | 380.50 | 173.91 | 1,009.04 | 736.84 | 574.85 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 743.33 | 490.65 | 258.18 | 480.18 | 195.73 |
Net Cash From Operating Activities | 1,322.85 | 664.64 | 2,987.80 | 2,215.17 | 1,641.65 |
Property & Equipment | -814.71 | -86.08 | 0.00 | -1,113.28 | -662.15 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -167.15 | -0.57 | -2,070.75 | 40.67 | 40.19 |
Other Investing Activities | 2.04 | 0.00 | -2.04 | 0.00 | 0.00 |
Net Cash from Investing Activities | -979.83 | -86.65 | -2,072.79 | -1,072.62 | -621.96 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -77.40 | 1.43 | -297.28 | -268.19 | -129.82 |
Issuance (Repayment) of Debt | 1,471.24 | 0.00 | -1,000.00 | -1,000.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -430.96 | -213.42 | -854.85 | -648.67 | -427.55 |
Other Financing Activities | -18.26 | 0.00 | 3.38 | 0.00 | 0.00 |
Net Cash from Financing Activities | 944.61 | -212.00 | -2,148.75 | -1,916.86 | -557.37 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1,287.63 | 365.99 | -1,233.74 | -774.30 | 462.33 |
Cash at Beginning of Period | 477.01 | 477.01 | 1,710.75 | 1,710.75 | 1,710.75 |
Cash at End of Period | 1,764.64 | 843.00 | 477.01 | 936.45 | 2,173.08 |
Diluted Net EPS | 0.23 | 0.01 | 1.11 | 0.16 | 0.50 |